[{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"CLS003","moa":"\nNKCC2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"CLS003","moa":"\nNKCC2","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"CLS003","moa":"\nNKCC2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"BiomX","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BX005-A","moa":"Bacteria microbiome","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"7","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Centre for Human Drug Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"11","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Centre for Human Drug Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Undisclosed","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"1","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Oncology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Leiden University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Leiden University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Leiden University Medical Center"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase I","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Biofrontera","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Biofrontera","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Biofrontera","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Biofrontera","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Amenamevir","moa":"Helicase primate complex","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Amenamevir","moa":"Helicase primate complex","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amenamevir","moa":"Helicase primate complex","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amenamevir","moa":"Helicase primate complex","graph1":"Undisclosed","graph2":"Phase I","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amenamevir","moa":"Helicase primate complex","graph1":"Undisclosed","graph2":"Phase I","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"AOBiome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Licensing Agreement","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Maruho","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Wipes","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Wipes","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"CLS006","moa":"NKCC2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Norepinephrine transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Digoxin","moa":"Sodium\/potassium-transporting ATPase","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"BiomX","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BX005","moa":"Staphylococcus aureus load","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"7","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"BiomX","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Microorganism","year":"2021","type":"Agreement","leadProduct":"BX005","moa":"Staphylococcus aureus load","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"7","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"CLS001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"CLS001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"CLS001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Evommune","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Maruho","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Maruho
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
